Published in Hepatitis Weekly, April 8th, 2002
The nucleoside analogue MIV-210 inhibits HBV and HIV in cell culture and in vivo: Both HIV and HBV develop resistance to present therapies but MIV-210 shows effect against such resistant virus in cell cultures.
In a hepatitis B in vivo model MIV-210 shows a more potent effect than lamivudine, the only antiviral drug presently on the market for hepatitis B treatment. In an in vivo model for HIV infection MIV-210 is about 10 times more potent then...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly